(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 April 2010 (29.04.2010)

PCT

(10) International Publication Number
WO 2010/046338 A1

(51) International Patent Classification:
A61K 9/127 (2006.01) *A61P 35/00* (2006.01)
A61K 39/00 (2006.01) *A61P 37/04* (2006.01)

(21) International Application Number:
PCT/EP2009/063656

(22) International Filing Date:
19 October 2009 (19.10.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/107,095 21 October 2008 (21.10.2008) US

(71) Applicants *(for all designated States except US)*: **DOMANTIS LIMITED** [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). **LIPOTEK PTY LTD** [AU/AU]; Innovations Building, 124 Eggleston Road, Acton, Australian Capital Territory 0200 (AU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALTIN, Joseph** [AU/AU]; Liptek Pty Ltd, Innovations Building, 124 Eggleston Road, Acton, Australian Capital Territory 0200 (AU). **ATMOSUKARTO, Ines** [ID/AU]; Lipotek Pty Ltd, Innovations Building, 124 Eggleston Road, Acton, Australian Capital Territory 0200 (AU). **DE WILDT, Rudolf, Maria** [NL/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **PARISH, Christopher** [AU/AU]; Lipotek Pty Ltd, Innovations Building, 124 Eggleston Road, Acton, Australian Capital Territory 0200 (AU). **PRICE, Jason** [AU/AU]; Lipotek Pty Ltd, Innovations Building, 124 Eggleston Road, Acton, Australian Capital Territory 0200 (AU).

(74) Agents: **FURLONG, Isla, Jane** et al.; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: COMPOSITION FOR TARGETING DENDRITIC CELLS

FIGURE 1



(57) Abstract: The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-DC-SIGN immunoglobulin single variable domain; and c) a carrier which carries a) and b). The invention further relates to formulations, compositions and devices comprising such anti-DC-SIGN molecules and their use as a medicament and in the treatment of cancer, suitably melanoma.

WO 2010/046338 A1

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*